Overlapping Gene Expression and Molecular Features in High-Grade B-Cell Lymphoma
Open Access
- 30 September 2024
- journal article
- research article
- Published by MDPI AG in Journal of Molecular Pathology
- Vol. 5 (4) , 415-436
Abstract
Aggressive B-cell lymphoma encompasses Burkitt lymphoma (BL), diffuse large B-cell lymphoma (DLBCL), and, as per the 2016 WHO classification, high-grade B-cell lymphoma (HGBL) not otherwise specified (NOS) and HGBL double/triple hit (DH/TH). However, the diagnostic distinction of HGBL from BL and DLBCL is difficult by means of histology/immunostaining in a substantial number of patients. This study aimed to improve subtyping by the identification of molecular features of aggressive B-cell lymphomas, with a specific focus on HGBL. To this end, we performed a comprehensive gene expression and mutational pattern analysis as well as the detection of B-cell clonality of 34 cases diagnosed with BL (n = 4), DLBCL (n = 16), HGBL DH (n = 8), and HGBL NOS (n = 6). Three distinct molecular subgroups were identified based on gene expression, primarily influenced by MYC expression/translocation and cell proliferation. In HGBL, compared to BL, there was an upregulation of PRKAR2B and TERT. HGBL DH exhibited elevated expression of GAMT and SMIM14, while HGBL NOS showed increased expression of MIR155HG and LZTS1. Our gene mutation analysis revealed MYC, ARID1A, BCL2, KMT2D, and PIM1 as the most affected genes in B-cell lymphoma, with BCL2 and CREBBP predominant in HGBL DH, and MYC and PIM1 in HGBL NOS. Clonality analysis of immunoglobulin heavy and light chain rearrangements did not show distinguishable V- or J-usage between the diagnostic subgroups.Keywords
Funding Information
- Charité Medical University, Berlin
This publication has 68 references indexed in Scilit:
- The fifth edition of the WHO classification of mature B‐cell neoplasms: open questions for researchThe Journal of Pathology, 2024
- Alternative genetic alterations of MYC, BCL2, and/or BCL6 in high‐grade B‐cell lymphoma (HGBL) and diffuse large B‐cell lymphoma (DLBCL): Can we identify different prognostic subgroups?Genes, Chromosomes and Cancer, 2023
- ClinVar Miner: Demonstrating utility of a Web-based tool for viewing and filtering ClinVar dataHuman Mutation, 2018
- MYC rearranged B-cell neoplasms: Impact of genetics on classificationCancer Genetics, 2016
- Bone morphogenetic proteins inhibit CD40L/IL‐21‐induced Ig production in human Bcells: Differential effects of BMP‐6 and BMP‐7European Journal of Immunology, 2011
- Inhibiting NF-κB activation by small molecules as a therapeutic strategyBiochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms, 2010
- Signaling through cAMP and cAMP-dependent protein kinase: Diverse strategies for drug designBiochimica et Biophysica Acta (BBA) - Proteins and Proteomics, 2008
- BIC and miR‐155 are highly expressed in Hodgkin, primary mediastinal and diffuse large B cell lymphomasThe Journal of Pathology, 2005
- Frequent expression of the Epstein–Barr virus (EBV)‐induced gene, EBI3, an IL‐12 p40‐related cytokine, in Hodgkin and Reed–Sternberg cellsThe Journal of Pathology, 2002
- A tandemly repeated sequence at the termini of the extrachromosomal ribosomal RNA genes in TetrahymenaJournal of Molecular Biology, 1978